Quick Look
Oxford University begins human trials for the world's first AI-designed vaccine, targeting Crimean-Congo haemorrhagic fever (CCHF), a deadly virus with 40% mortality rates and no widely approved vaccine, using AI to accelerate development by analyzing genetic data to identify immune response triggers.
AI-generated summary
Oxford University begins human trials for the world's first AI-designed vaccine, targeting Crimean-Congo haemorrhagic fever (CCHF), a deadly virus with 40% mortality rates and no widely approved vaccine, using AI to accelerate development by analyzing genetic data to identify immune response triggers.